Sociedad Americana de Hirudoterapia

Leech Substance P Modulator

Salivary factor reported to modulate the substance P / neurokinin-1 nociceptive pathway.

Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech Substance P Modulator compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech Substance P Modulator14 kDa
Molecular weight (kilodaltons) of Leech Substance P Modulator (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Salivary factor reported to modulate the substance P / neurokinin-1 nociceptive pathway.
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

Leech substance P modulator is documented mechanistically only; no human evidence. Hypothesized nociceptive modulation does NOT establish clinical analgesic efficacy, and no FDA-approved derivative exists.

Molecular Profile

Category
Analgesic
Evidence tier
Preclinical
Molecular weight
14,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Leech Substance P Modulator molecular structure

Biological Targets

  • substance P signaling
  • neurokinin-1 receptor pathway

Key Citations

  1. Liu Z et al. (2019), Parasit Vectors

External Resources

    Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.